



Welcome to our September 2015 newsletter. We hope you enjoy the update and welcome any feedback or enquires at: [info@resonancehealth.com](mailto:info@resonancehealth.com)

## New Distributor in Canada

Resonance Health has appointed a Canadian distributor to expand on our activities in Canada, improve market access and to raise awareness in new clinical communities, both for FerriScan® and HepaFat-Scan®.

KNS Canada is a very successful distributor for non-invasive tests in the hepatology and gastroenterology markets across the country, with a strong infrastructure of representatives.

This relationship will also provide additional exposure at Canadian health events. The first of these was the Pan-Canadian Thalassemia Conference which took place in Toronto on September 25-26th, attended by KNS.

For local enquiries, please contact Shahid Khandler at [shahid.khandler@knsCanada.com](mailto:shahid.khandler@knsCanada.com) or [Click for further details...](#)

## Customer Focus: St Mary's Hospital Celebrates 1000 FerriScans from Perth to Paddington!



Left to right: Melanie Baxter, Resonance Health, Christie Batkin (7), one of over 1000 patients benefiting from FerriScan at the Imperial Trust and Dr Alavi, Consultant Paediatric Radiologist who leads the team providing the FerriScan service at St Mary's.

The increasing rate of FerriScan® adoption by clinicians worldwide has seen five hospitals recently reach a milestone of 1000 scans performed in routine patient management. Among these is St Mary's at the Imperial Trust in London, who introduced FerriScan four years ago to optimise iron monitoring and reduce the need for liver biopsy.

Celebrations were held at St Mary's Radiology Department to mark this impressive achievement and to celebrate our successful collaboration. The celebrations were presided over by radiologist Dr Alavi, and lead Haematologist Dr Josu de La Fuente from St Mary's, representatives from four patient societies and Melanie Baxter, Global Marketing Director of Resonance Health. Dr Alavi said; "We aim to incorporate the very best diagnostics into care pathways for haemoglobinopathy patients and those at risk of iron overload. The introduction of FerriScan has significantly improved health outcomes and the excellent collaboration with Resonance Health to provide 1000 patients with access to optimised monitoring is certainly something to be celebrated."

Other centres achieving this considerable target recently are:

- Whittington Hospital, London
- University College London
- Toronto General Hospital
- Hospital for Sick Children, Toronto

[Click for further details...](#)

## FerriScan Goes Mobile in the UK!

In partnership with Alliance Medical, FerriScan has now got wheels in the UK via their newly certified Mobile MRI scanner. The new mobile scanner is available to be booked for a day or longer for any hospitals where access or capacity is an issue.

This is a unique development for FerriScan as we can now bring the mobile scanner to a Trust's location rather than patients having to travel further afield. An additional benefit for any Trust is that Alliance Medical operate for a 12 hour day with 11 hours of scanning. Should there be spare hours on the scanner where FerriScan is not required, they would be more than happy to scan traditional MRI patients on an unreported basis.

For more information on booking, logistics and costs to book the scanner please contact the Alliance Medical business development department on 01926 482222.



*Alliance Medical's FerriScan-certified MRI Scanner on Wheels*

## R&D Round-up



### Measuring Iron in Bone Marrow

Chief Scientific Officer, Professor Tim St Pierre has collaborated on research with an institute in the UK which has successfully resulted in a paper being accepted for publication in a peer-reviewed journal. Using existing FerriScan image data, R2 was measured as a surrogate biomarker for iron in the spleen, kidneys, and bone marrow. The research identified patterns of iron distribution for different tissues in various iron overload conditions, including sickle cell disease (SCD) and non-transfusion dependent thalassemia (NTDT). Further details of the full paper will be made available on our website following publication.

In a local research setting, Resonance Health has since provided bone marrow R2 analyses and is now in discussion with other potential European research partners on further bone marrow iron studies, for example in patients with myelodysplastic syndrome (MDS). As existing FerriScan data can potentially be used, customers with an interest in measuring bone marrow R2 in the research setting are invited to contact us at [info@resonancehealth.com](mailto:info@resonancehealth.com).

### AASLD Conference Fibrosis Abstract Accepted

Professor Tim St Pierre's abstract on Fibrosis has been accepted by the American Association for the Study of Liver Disease (AASLD) to be held in San Francisco on November 14-17th.

Resonance Health will be participating in the 3rd Liver Forum meeting that precedes AASLD and exhibiting at the main conference. Please visit us at exhibition booth number 241 to hear more about our latest research developments and updates on HepaFat-Scan and FerriScan.


# HepaFat-Scan® Update

With the initiation of our Australian Liver Surgery Multi-Centre Clinical Trial, the Children's Hospital of Atlanta NAFLD Study, and the UK Hyperferritinemia Study in the last three months, Resonance Health is offering free set up of HepaFat-Scan for existing FerriScan centres for use in routine clinical practice or research.

Please contact

info@resonancehealth.com to discuss the potential application of HepaFat-Scan in the surgical setting and in NAFLD / NASH, or opportunities to collaborate on case studies or in research settings.

For more information on HepaFat-Scan in a clinical context please [click here](#)



## See us at:

9th Annual Sickle Cell & Thalassemia Advanced Conf.  
London, 6-8th Oct. [Click for further details...](#)

AASLD, San Francisco, US 14-17th Nov. Stand 241 [Click for further details...](#)

ASH 2015 - Orlando, Florida 5-8th Dec. Stand 969 [Click for further details...](#)

## Next Issue

- *TIF Pan Asian Conference Report - Prof Tim St Pierre as key speaker on Iron Monitoring*
- *New Fibrosis Project Update*

## Team Member in Focus: Wenjie Pang, Technical and Research Manager



Wenjie hails from China, where he enjoyed a successful career researching magnetism in different forms. He came to the University of Western Australia as a visiting research fellow in the Department of Physics. Following an International Scholarship to study for his PhD and some time at the University of Colorado in the US, Wenjie became one of the first employees of Resonance Health in 2005.

Wenjie's roles in the company have been pivotal and varied. He has been heavily involved in R&D across FerriScan, HepaFat-Scan and liver fibrosis measurement and his work has also resulted in a significant shortening of the MRI scan time required for FerriScan. Most recently Wenjie has worked closely with the marketing team to explore the market in China and provide clinical education.

Since moving to Western Australia, Wenjie and wife greeted the arrival of their second child, and he enjoys playing bridge and various sports in his spare time.

Resonance Health  
278 Stirling Highway Claremont WA 6010 Australia  
[www.resonancehealth.com](http://www.resonancehealth.com)  
+61 8 9286 5300

You are receiving this email as you are registered in FAST or have expressed interest in Resonance Health and/or our services

**Preferences | Unsubscribe**

TWEET

FORWARD

